– USA, CA – AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today the appointment of Dr. Joanne Hackett (Ph.D.) as the Non-Executive Chair of its Board of Directors, succeeding Dr. Greg Bailey who remains a member of the Board of Directors.
About Dr. Joanne Hackett
Dr. Joanne Hackett joined the Board of Directors in December 2021.
Dr. Hackett is the Head of Genomic and Precision Medicine at IQVIA, a world leader in using data, technology, advanced analytics, and expertise to help customers drive healthcare forward. From 2017 to 2020, Dr. Hackett served as CCO of Genomics England, owned by the Department of Health and Social Care in the United Kingdom. During 2016 and 2017, Dr. Hackett served as CCO and Interim CEO of the Precision Medicine Catapult, which was established in the United Kingdom with the goal of developing and commercializing precision medicine.
Dr. Hackett holds a Ph.D. in Molecular Genetics from the University of New Brunswick.
About AgeX Therapeutics
AgeX Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics to treat human diseases to increase healthspan and combat the effects of aging. AgeX’s PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform induced Tissue Regeneration aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. HyStem is AgeX’s delivery technology to stably engraft PureStem or other cell therapies in the body. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.
For more information: https://www.agexinc.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
